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Dynamics of S. aureus carriage 427Colonisation;
spa-typing;
Carriage durationMethods: 1123 adults attending five Oxfordshire general practices had nasal swabs taken. 571
were re-swabbed after one month then every two months for median two years. All S. aureus
isolates were spa-typed. Risk factors were collected from interviews and medical records.
Results: 32% carried S. aureus at recruitment (<1% MRSA). Rates of spa-type acquisition were
similar in participants S. aureus positive (1.4%/month) and negative (1.8%/month, PZ 0.13) at
recruitment. Rates were faster in those carrying clonal complex (CC)15 (adjusted (a)PZ 0.03)
or CC8 (including USA300) (aPZ 0.001) at recruitment versus other CCs. 157/274 (57%) partic-
ipants S. aureus positive at recruitment returning 12 swabs carried S. aureus consistently, of
whom 135 carried the same spa-type. CC22 (including EMRSA-15) was more prevalent in long-
term than intermittent spa-type carriers (aPZ 0.03). Antibiotics transiently reduced carriage,
but no other modifiable risk factors were found.
Conclusions: Both transient and longer-term carriage exist; however, the approximately con-
stant rates of S. aureus gain and loss suggest that ‘never’ or truly ‘persistent’ carriage are rare.
Long-term carriage varies by strain, offering new explanations for the success of certain S.
aureus clones.
ª 2014 The Authors. Published by Elsevier Ltd on behalf of the The British Infection Associa-
tion.Open access under CC BY license. Introduction
Staphylococcus aureus is an important cause of infections in
both primary and secondary care. Carriage prevalences of
w30% have been found consistently in studies performed
over six decades,1 with the anterior nares the primary
site of colonisation.1e3 Nasal carriers are at greater risk
of infection than non-carriers4e7 and the carried and inva-
sive strains are indistinguishable in w80% of cases.5,8 Non-
carriers of S. aureus have a higher mortality following S.
aureus bacteraemia suggesting recent S. aureus acquisition
around the time of infection is associated with poorer sub-
sequent outcome.5
The dynamic nature of S. aureus carriage creates
complexity for cross-sectional and longitudinal studies,
with people acquiring and losing all genotypes of S. aureus
(the species level) and also acquiring and losing different
genotypes within S. aureus.9 For example, one study found
multiple genotypes were present in 7% of carriage
samples.10
Rather than considering S. aureus loss and acquisition as
separate events, studies have almost universally combined
both these aspects and classified individuals as “persis-
tent”, “intermittent” or “non” carriers. “Persistence” has
most commonly been defined on the basis of (i) >80% pos-
itivity of 10e12 swabs taken weekly over w3 months (not
considering strain-type)11 or (ii) two positive cultures one
week apart, since this had good performance for predicting
persistent carriage defined by definition (i) in one study.12
Human polymorphisms associated with “persistent” car-
riage using definition (ii) have been identified,13 but bacte-
rial factors have not, to date, been associated with
different carriage types. Very long-term carriage and strain
switching undoubtedly occur; for example 12/17 “persis-
tent” S. aureus carriers according to definition (i) carried
S. aureus on a single swab taken eight years later, but
only three carried highly similar S. aureus strains.11 Howev-
er, few studies appear to have repeatedly sampled individ-
uals over intermediate periods of >1 years,14,15 or
systematically investigated carried genotypes over these
timescales. The rates of acquisition and median carriageduration of newly acquired strains, and the rates of loss
of individual strains present in an initial sample with un-
known acquisition date, have also rarely been described
outside the specific setting of methicillin-resistant strains
in hospitalised patients.16e18 Longer-term follow-up might
further support experimental studies which found no
distinction between non- and intermittent carriers defined
following definition (i) in terms of rates of loss of carriage of
a nasal inoculum.19
Here we investigate S. aureus nasal carriage in individ-
uals from primary care, swabbed bi-monthly for up to 36
months. We spa-typed all S. aureus isolates to identify
acquisition and loss that would be unrecognised at the spe-
cies level. Our primary objective was to describe the dy-
namics of S. aureus carriage (loss, gain) in the general
population, and to investigate potential risk factors, in
particular the contribution from particular spa-types.Methods
Study population
Eligible participants were consecutive adults aged 16
years attending one of five Oxfordshire general practices
(each a group of family doctors) in the Thames Valley
Primary Care Research Partnership (all in the catchment
area for the Oxford University Hospitals (OUH) NHS Trust).
All participants provided written informed consent. 200
participants were recruited from each general practice
sequentially over December 2008eDecember 2009, in
age/sex strata approximately representing the UK popu-
lation. Recruitment was completed in each practice
before starting in the next. To increase numbers of
younger participants, students registering at one practice
were recruited during the University Freshers’ week. For
the first four general practices, we invited only those
participants whose recruitment swab grew S. aureus to
continue longitudinal follow-up. All participants from
the last practice and all students were invited to continue
longitudinal follow-up. Assuming 35% participants were S.
428 R.R. Miller et al.aureus positive at recruitment and followed longitudi-
nally, recruiting 1000 adults provided >80% power to
detect differences of >15% in risk factors between inter-
mittent and continuous carriers.17,20e22 The study was
approved by Oxfordshire Research Ethics Committee B
(08/H0605/102).
Nasal swabs were taken by all participants on recruit-
ment under research nurse supervision. A dry cotton swab
was placed in the tip of both nostrils and rotated three
times. All S. aureus positive participants, all students and
all participants from the last practice were posted a nasal
swabbing kit one and two months after recruitment, and
then every two months thereafter. The swabbing technique
was demonstrated on recruitment and explained in a leaflet
included with each kit. Swabs were returned by post in
charcoal medium (typically <1 week), and stored at 4 C
on receipt before processing (processing took <1 week;
up to two weeks in total). As the study objective was to
investigate S. aureus dynamics, isolation protocols focussed
on identifying all strains, even those present at low fre-
quencies. To increase the sensitivity of culture, swabs
were therefore incubated overnight at 37 C in 5% NaCl
enrichment broth (E&O Laboratories, Bonnybridge, UK). A
5 mm loop-full of broth was sub-cultured onto SASelect
chromogenic agar (Bio-Rad, Limerick, Ireland) and incu-
bated at 37 C overnight. Pink colonies were tested further
using DNAse, catalase and Staphaurex tests following stan-
dard procedures.23 Samples positive in all three tests were
presumed to be S. aureus. A selection of pink colonies from
the SASelect agar were resuspended in saline from which
one aliquot was stored as glycerol stock at 20 C and
another added to 10 ml 0.85% Saline (E&O Laboratories)
and 50 ml TE buffer (Sigma, Dorset, UK), heated at
99.9 C for 10 min, then centrifuged to separate the super-
natant. From this, 50 ml was removed and stored at 20 C
as a crude chromosomal DNA extract.
spa-typing was performed as described,24 with DNA
amplification and sequencing using the Microlab Star Liquid
Handling Workstation (Hamilton Robotics Ltd, Birmingham,
UK). Chromatograms for the spa gene were assembled using
Ridom StaphType.24 Samples with mixed chromatograms
were re-cultured and six-12 colonies separately typed.
spa-types were grouped into spa-Clonal Complexes (CCs)
using BURP clustering, and CCs labelled as their MLST equiv-
alent for ease of comparison with other studies.25
Epidemiological and healthcare information was
collected from a structured questionnaire at recruitment,
general practice and OUH records (see Supplementary
Methods). After two years follow-up, general practice and
OUH records were re-reviewed to ascertain antimicrobial
use and inpatient admissions throughout follow-up.Outcome definitions
(1) Loss of carriage (primary outcome)
Confirmed loss of carriage was defined as two consecutive
negative swabs (or two consecutive swabs without the
previous spa-type for analysis of spa-types (spa-level)).
The time of confirmed loss was taken as the first of the
two negatives. Single isolated negatives were ignored(given potential limited efficacy of self-swabbing). Partic-
ipants with only their last swab negative were censored at
the preceding positive swab. Thus loss analyses included
only participants returning 2 swabs after the first posi-
tive to enable any loss to be confirmed. Loss rates over
time were estimated using flexible parametric hazard
models.26
(2) Acquisition
S. aureus acquisition was defined as positive growth (or a
new spa-type) after confirmed prior absence (two consecu-
tive negatives, or absence of spa-type). Thus if the first
swab after recruitment (post-recruitment swab) in individ-
uals S. aureus negative at recruitment (recruitment-nega-
tives) grew S. aureus (or grew a new spa-type in
participants S. aureus positive at recruitment (recruit-
ment-positives)), this was not counted as acquisition but
was presumed to represent a false-negative result at
recruitment. Acquisition analyses therefore also included
only participants returning 2 swabs after the first positive.
Since nasal evolution can produce small changes in
repeat numbers, new spa-type acquisition was defined as
having >2 differences from first positive swab25 (see
Supplementary Table 1 for grouping). Results were similar
allowing any spa difference to count as a new spa-type
acquisition.
All individuals were to be followed for two years (total
14 swabs) under the original protocol. If an individual did
not return three consecutive swabs, no further swabs were
sent. Following a protocol amendment, at two years further
consent was sought for longer follow-up in those persis-
tently negative or persistently positive (allowing single
intermitted negatives) for S. aureus to enable longer-term
rates of gain and loss to be estimated in those remaining
at risk. Participants were considered formally lost to
follow-up if they returned their last swab <22 months
from enrolment and >4 months before the data cut-off
(23 January 2012).
Statistical analysis
STATA 11.2 was used for all analyses, which included data
to 23 January 2012 (minimum two years expected follow-
up). Cox regression was used to identify independent
predictors of loss and acquisition. Multinomial logistic
regression was used to identify predictors of long-term
carriage with the same spa-type versus intermittent car-
riage, and predictors of never observed versus intermit-
tent carriage (see Supplementary Methods). The modal
CC was defined as the most frequently observed CC per
individual.
Results
S. aureus at recruitment
Of 1123 enrolled individuals, 360 (32%) were S. aureus pos-
itive at recruitment. Four hundred and eighty-three (43%)
were male and the median age of all 1123 individuals was
55 (inter-quartile range (IQR)) [range] (37e67) [16e94]
Dynamics of S. aureus carriage 429years. Nine individuals had MRSA (0.8%) at recruitment, all
Epidemic-(E)MRSA-15 (N Z 3) or EMRSA-16 (N Z 6). Male
sex, being in current employment, longer time since district
nurse appointment, ever having been an inpatient and
treatment for a skin condition within the last 30 days
were associated with higher S. aureus prevalence in a
multivariate model (P < 0.0001, 0.02, 0.04, 0.03, 0.03
respectively) (Supplementary Table 1).S. aureus carriage during follow-up
To investigate S. aureus loss and (re-)acquisition, the 360
individuals positive at recruitment (recruitment-positive)
plus a further 211 S. aureus negative at recruitment (82
from the last general practice, 129 students, see
Methods) were followed for a median (IQR) 2.0 (1.8e2.2)
years, returning a median (IQR) 1411e15 swabs (range
1e20). Three (0.5%) individuals died and 121 (21%) were
lost to follow-up (25 (4%) did not return any swabs post-
baseline, 53 (9%) missed returning three consecutive swabs
and were removed from follow-up and 43 (8%) moved from
the area or withdrew from the study) (Fig. 1,
Supplementary Fig. 1). S. aureus grew from 3749 of 7009
post-recruitment swabs returned (53%) and was subse-
quently recovered from 73 (35%) individuals S. aureus nega-
tive at recruitment (recruitment-negatives), ten (5%) at the
first swab after recruitment. All S. aureus were spa-typed;
of the 297 spa-types observed, 197 (66%) were only seen in
one individual. The 297 spa-types formed 157 groups with
2 differences, 82 were singletons and 22 could not be
grouped because they were too short (Supplementary
Table 2).Figure 1 StudyCarrier index
Based on the carrier index (proportion of S. aureus positive
swabs/swabs returned), just under half of the recruitment-
positives carried S. aureus consistently throughout the
study, and just over 60% of recruitment-negatives never
carried S. aureus (Fig. 2). However, most of those with in-
termediate carrier indices had distinct phases of carriage
of specific spa-types and phases of non-carriage. In partic-
ular, recruitment-positives lost carriage at similar rates
throughout the study, leading to approximately equal
numbers with carrier indices below one. We therefore esti-
mated the time course over which recruitment-negatives
became positive and recruitment-positives gained a new
spa-type (“gain”, Fig. 3), and over which recruitment-
positives became negative and recruitment-negatives who
had become positive then lost carriage (“loss”, Fig. 4).
S. aureus acquisition
162 (30%) of 544 participants returning 2 post-recruitment
swabs acquired a new spa-type (with >2 differences)
during follow-up, at a rate of 1.5% (95% CI 1.3e1.8%) per
month. MRSA (EMRSA-15) was acquired by one individual.
Similar percentages of recruitment-positives (29%) and
recruitment-negatives (32%) acquired a new spa-type, and
acquisition rates were similar (1.4% (95% CI 1.2e1.7%) and
1.8% (1.4e2.3%) per month respectively; log-rank
P Z 0.13, Fig. 3). There was no suggestion that acquisition
rates plateaued over time (Fig. 3). Age was the strongest
recruitment factor associated with rate of acquisition,
which was faster in younger individuals (adjusted
P Z 0.01) (Table 1, Supplementary Table 2). Acquisitionflow diagram.
Figure 2 Carrier index.
430 R.R. Miller et al.rates also varied independently with recruitment CC (global
adjusted P Z 0.04); being significantly faster in those with
CC8 (adjusted P Z 0.001), the CC including USA300, and
with CC15 (adjusted P Z 0.03).
In time-updated models including post-recruitment fac-
tors, having S. aureus isolated from the previous swab
significantly decreased the rate of acquisition of a new
spa-type (adjusted for Table 1 factors hazard ratio (a)
HR Z 0.61 (0.40e0.91), P Z 0.02). Based on the analysis
of recruitment factors above, we divided carriage of pre-
existing S. aureus into CC8, CC15 or another CC, and found
significant variation in this effect across these clonal com-
plex groups (P Z 0.002). Compared to those without pre-
existing S. aureus, acquisition of a new spa-type occurred
at similar rates in those with CC15 (aHR Z 1.18
(0.60e2.31) and possibly at even higher rates in those
with pre-existing CC8 (aHRZ 2.03 (0.79e5.20); acquisitionFigure 3 Months to acquisition of a new S. aureus spa-type in
recruitment-positives and negatives. Note: not counting a spa-
type first observed at the first post-recruitment swab as an
acquisition, see Methods.of a new spa-type was only reduced in those with other CCs
(aHR Z 0.50 (0.32e0.76)). Anti-staphylococcal antibiotics
(see Supplementary Methods) were taken by 158/571
(28%) participants during the study; their use in the interval
between the previous and current swab did not signifi-
cantly affect S. aureus acquisition (aHR Z 0.97
(0.49e1.91), P Z 0.93). However, having received antibi-
otics more than two swabs ago increased the rate of S.
aureus acquisition (aHR Z 1.66 (1.16e2.38), P Z 0.006),
suggesting that individuals who lose S. aureus due to anti-
biotics are likely to re-acquire. There was no evidence that
current inpatient admissions significantly affected S.
aureus acquisition at the species or spa-level (adjusted
P > 0.3) and the effects of previous antibiotics and co-
colonisation remained when adjusted for one another,
that is, were independent.S. aureus loss
We first considered loss of S. aureus spa-type in those in
whom the date of acquisition was observed, that is those
who acquired a new spa-type in the study and subse-
quently returned 2 swabs (n Z 145; Fig. 4(a)). 98
(68%) subsequently lost this spa-type (53/87 (61%)
recruitment-positives and 45/58 (78%) recruitment-
negatives, log-rank PZ 0.05). Median (IQR) carriage dura-
tion of acquired spa-types was two2e10 months in
recruitment-negatives and two (2e>18) months in
recruitment-positives. Loss rates varied substantially
over time since acquisition (Supplementary Fig. 1(a)),
averaging 19%/month (95% CI 15e24%) in the first four
months versus 5%/month (3e8%) subsequently (3%/month
(2e6%) in recruitment-positives versus 10%/month
(5e18%) in recruitment-negatives) with no evidence of
further slowing during the study.
We then considered loss of all S. aureus at the species
level (Fig. 4(b)). 134 (39%) of 346 recruitment-positives
Figure 4 Months to confirmed loss of S. aureus in recruitment-positives and negatives. (a) Confirmed loss of spa-type acquired
during the study. (b) Confirmed loss of all S. aureus, and of S. aureus spa-type present at recruitment in recruitment-positives.
Note: when the first S. aureus positive swab contained multiple spa-types, time to loss of spa-type from recruitment swab was
the first time any of these spa-types was lost.
Dynamics of S. aureus carriage 431returning 2 post-recruitment swabs subsequently lost all
S. aureus during the study. Whilst overall loss rates were
greater in recruitment-negatives subsequently observed
to carry S. aureus (log-rank P < 0.0001), the difference in
loss rates was largest early on (Supplementary Fig. 1(b));
after four months, losses occurred at low and more similar
rates in both groups (2%/month (95% CI 1e2%) in
recruitment-positives versus 6%/month (3e10%) in
recruitment-negatives). First confirmed absence of any
spa-type present at recruitment occurred at a slightly
faster rate than loss of all S. aureus (Fig. 4(b)), indicating
lost strains were often merely replaced. Age was indepen-
dently associated with rate of spa-type loss, which wasfaster in younger individuals (adjusted P Z 0.05;
Table 1). More recent outpatient exposure, having more
household members and being negative for S. aureus on
recruitment were independent predictors of loss (adjusted
P Z 0.001, P Z 0.03 and P < 0.0001 respectively). There
was no evidence of an impact of recruitment CC on spa-
type loss (adjusted global P Z 0.42).
In time-updated models including post-recruitment fac-
tors, having multiple spa-types (differing by >2 repeats) in
the previous swab had no significant effect on loss at the
species level (adjusted for Table 1 factors aHR Z 0.64
(95% CI 0.23e1.74), P Z 0.38), but significantly increased
loss of the original pre-existing spa-type (aHR Z 3.40
Table 1 Recruitment factors independently associated with acquisition of a new spa-type or confirmed loss of a S. aureus spa-type.
Factor (determined
at recruitment)
(effect in
Cox model)
Acquisition of a new spa-type (N Z 523) P value Loss of spa-type (N Z 401) P value
Acquire
(N Z 157)
n (row %) or
median (IQR)
Do not
acquire
(N Z 366)
n (row %) or
median (IQR)
Hazard
ratio (95% CI)
from
multivariable
model
Number lose
(N Z 220) n
(row %) or
median (IQR)
Number
do not lose
(N Z 181)
n (row %) or
median (IQR)
Hazard ratio
(95% CI) from
multivariable
model
S. aureus details (included by design)
Recruitment-negative No 97 (29%) 242 (71%) 1.00 168 (50%) 169 (50%) 1.00
Yes 60 (33%) 124 (34%) 1.35 (0.82;2.22) 0.23 52 (81%) 12 (19%) 3.23 (2.07;5.02) <0.0001
CC present at
recruitment
CC30 (spa-CC021)
(reference
category)
23 (23%) 76 (77%) 1.00 global 0.04 45 (45%) 54 (55%) 1.00 global 0.42
CC15 (spa-
CC084)
16 (38%) 26 (62%) 2.01 (1.06;3.83) 0.03 22 (52%) 20 (48%) 1.31 (0.78;2.19) 0.31
spa-CC002 6 (26%) 17 (74%) 1.04 (0.42;2.57) 0.94 12 (55%) 10 (45%) 1.45 (0.76;2.77) 0.26
CC22 (spa-
CC005)
7 (29%) 17 (71%) 1.40 (0.60;3.27) 0.44 7 (29%) 17 (71%) 0.57 (0.26;1.27) 0.17
spa-CC127 6 (27%) 14 (73%) 1.36 (0.55;3.37) 0.51 13 (65%) 7 (35%) 1.46 (0.78;2.72) 0.24
spa-CC160 3 (21%) 11 (79%) 1.07 (0.32;3.59) 0.91 7 (50%) 7 (50%) 1.18 (0.53;2.65) 0.68
CC8 (spa-CC024) 7 (64%) 4 (36%) 4.50 (1.91;10.6) 0.001 7 (64%) 4 (36%) 1.28 (0.57;2.87) 0.55
Other CC 29 (27%) 77 (73%) 1.34 (0.78;2.33) 0.29 55 (52%) 50 (48%) 1.36 (0.91;2.03) 0.13
Participant characteristics (included by design)
Age (years) (Per 10 years
older)
40 (19;60) 54 (35;65) 0.85 (0.75;0.97)b 0.01 47 (22;62) 56 (37;67) 0.90 (0.81;1.00)c 0.05
Sex Female 84 (30%) 192 (70%) 1.00 175 (68%) 83 (32%) 1.00
Male 73 (30%) 174 (70%) 1.13 (0.81;1.56) 0.47 98 (50%) 98 (50%) 0.94 (0.71;1.25) 0.68
Student No 115 (27%) 318 (73%) 1.00 175 (52%) 163 (48%) 1.00
Yes 42 (47%) 48 (53%) 1.46 (0.86;2.47) 0.16 45 (71%) 18 (29%) 0.94 (0.58;1.52) 0.80
Participant behaviour
Number of other
household
members
Lives alone 13 (19%) 54 (81%) 1.00 24 (44%) 31 (56%) 1.00
1 household
member
55 (25%) 162 (75%) (trend, per
category higher)
74 (47%) 85 (53%) (trend, per category higher)
2/3 household
members
67 (37%) 116 (63%) 1.19 (0.95;1.51) 0.13 91 (62%) 55 (38%) 1.22 (1.02;1.47) 0.03
4 or more/shared 22 (39%) 34 (61%) 31 (76%) 10 (34%)
Healthcare exposure
Days since last
outpatient
appointmenta
(Per year longer) 322 (97;921) 299 (86;1106) 0.95
(0.90;1.00)
0.06 324
(106;900)
294
(84;1174)
0.93
(0.89;0.97)
0.001
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Dynamics of S. aureus carriage 433(2.15e5.37), P < 0.001). Thus observations of multiple spa-
types were commonly followed by replacement of the orig-
inal with the new spa-type. Recent use of anti-
staphylococcal antibiotics independently increased the
rate of S. aureus loss at the species level (aHR Z 2.51
(95% CI 1.54e4.10), P < 0.0001) (similar results for spa-
type loss). There was no evidence that current inpatient
admissions significantly affected S. aureus loss at the spe-
cies or spa-level (adjusted P > 0.3).Exploration of long-term carriage patterns
(i) Long-term consistent carriage at the S. aureus species
level
To explore whether a consistent (long-term) carriage
phenotype existed in our study, we combined the carrier
index (Fig. 2) and time-to-loss (Fig. 4(b)) approaches to es-
timate the proportion of recruitment-positives observed to
have carried S. aureus consistently in their first two, three,
four, five etc swabs (Fig. 5(a)). The proportion of long-term
consistent carriers declined linearly at least through to the
first 12 swabs (w24 months). After 12 swabs, confidence in-
tervals were wide, and results were compatible with the
ongoing low rates of loss seen in Supplementary Fig. 1.
For example, of 140 individuals who were classified as
consistent long-term carriers based on their first 12 swabs
and who returned 14 swabs, 11 (8%) subsequently lost
carriage on two consecutive samples. Allowing single inter-
mittent negative swabs increased estimates of consistent
long-term carriers byw10%, but the relationship with num-
ber of swabs was similar (Fig. 5(a)). Of the 274
recruitment-positive participants returning 12 swabs,
157 (57%) never had two consecutive negative swabs, i.e.
could be considered to have carried consistently long-
term throughout the study. 4/61 (7%) recruitment-
negatives returning 12 swabs with 1 positive could
also be considered to have carried consistently long-term
throughout the study (i.e. plausibly had an initial false-
negative recruitment swab).
(ii) Long-term carriage at the S. aureus spa-type level
Of the 161 individuals without two consecutive nega-
tive swabs (i.e. defined long-term consistent carriers at
the species level), 92 (57%) carried a single spa-type
throughout without any other spa-type being observed,
45 (28%) carried a single spa-type throughout as well as
gaining/losing other types; and 24 (15%) did not carry
one spa-type consistently. Therefore 137/335 (41%) par-
ticipants ever observed to carry S. aureus were consistent
long-term carriers of the same spa-type, 135/274 (49%)
recruitment-positives and 2/61 (3%) recruitment-
negatives. Gaining/losing other spa-types was more com-
mon in persistent carriers of CC8 (3/3,100%) and CC15
(9/14,64%) than persistent carriers of other spa-types
(33/120,28%) (P Z 0.001), although numbers were small
so results may not be robust.
(iii) “Non-carriage”
Figure 5 Impact of duration of follow-up on classification of carriage phenotypes. (a) Percentage of recruitment-positives clas-
sified as consistent carriers. Note: for example, the percentages shown for 1-8 swabs are the proportions of recruitment-positives
with S. aureus isolated from all post-recruitment swabs (black line) or with only intermittent (i.e. not confirmed) no growth (grey
line). (b) Percentage of recruitment-negatives classified as non (“never observed”) carriers.
434 R.R. Miller et al.Taking a similar approach to explore a “never carriage”
phenotype, the percentage of recruitment-negatives clas-
sified as non-carriers continued to decline linearly with
increasing numbers of swabs. 90/151 (60%) recruitment-
negatives returning 12 swabs never grew S. aureus during
the study.Characteristics of different carriage phenotypes in
those returning ‡12 swabs
The characteristics of those carrying one spa-type consis-
tently long-term (allowing gain/loss of other spa-types),
Table 2 Impact of participant characteristics on long-term consistent carriage of a S. aureus spa-type versus intermittent carriage, and never observed carriage versus inter-
mittent carriage, in participants returning 12 swabs (w24 months).
Factor (effect in
multinomial
regression
model)
S. aureus long-term
consistent spa-type
carriers (N Z 136):
n (row %) or
median (IQR)
S. aureus
intermittent
carriers (N Z 192):
n (row %) or
median (IQR)
Long-term consistent
spa-type versus
intermittent carriage
Never observed
carriers (n Z 88):
n (row%) or
median (IQR)
Never observed versus
intermittent carriage
RR (95% CI) P value RR (95% CI) P value
Modal CC CC30 (spa-CC021)
(reference
category)
43 (41%) 62 (59%) 1.00 global 0.13 N/A N/A N/A
CC15
(spa-CC084)
14 (29%) 34 (71%) 0.49 (0.22;1.08) 0.08
spa-CC002 9 (33%) 18 (67%) 0.72 (0.28;1.88) 0.50
CC22
(spa-CC005)
16 (73%) 6 (27%) 3.17 (1.09;9.24) 0.03
spa-CC127 6 (33%) 12 (67%) 0.58 (0.19;1.75) 0.33
spa-CC160 5 (45%) 6 (54%) 0.96 (0.24;3.80) 0.95
CC8 (spa-CC024) 3 (30%) 7 (70%) 0.73 (0.16;3.35) 0.69
Other CC
(<10 people)
40 (46%) 47 (54%) 1.06 (0.56;1.99) 0.85
Participant characteristics at recruitment
Age (years) (Per 10 years) 60 (47;68) 50 (26;63) 1.05 (0.87;1.27)b 0.58 59 (41;65) 1.27 (1.01;1.59)c 0.04
Sex Female 58 (27%) 109 (50%) 1.00 51 (23%) 1.00
Male 78 (39%) 83 (42%) 1.58 (0.96;2.58) 0.07 37 (19%) 0.83 (0.48;1.43) 0.50
Student No 127 (36%) 155 (43%) 1.00 75 (21%) 1.00
Yes 9 (15%) 37 (63%) 0.41 (0.15;1.17) 0.10 13 (22%) 1.69 (0.60;4.78) 0.32
Participant behaviour at recruitment
Number of other
household
members
Lives alone 25 (45%) 22 (40%) 1.00 8 (15%) 1.00
1 household
member
71 (36%) 72 (37%) (trend, per category higher) 53 (27%) (trend, per category higher)
2/3 household
members
36 (27%) 77 (57%) 0.64 (0.45;0.92) 0.02 21 (16%) 0.81 (0.54;1.22) 0.32
4 or more/
shared
4 (13%) 21 (67%) 6 (19%)
Participant behaviour at recruitment
Days since last
outpatient
appointmenta
(Per year
longer)
289 (83;1087) 324 (105;909) 1.11 (1.03;1.21) 0.01 241 (48;1123) 1.00 (0.91;1.10) 0.98
Co-morbidities at recruitment
Has a long-term
illness
No 46 (25%) 93 (50%) 1.00 48 (27%) 1.00
Yes 90 (39%) 99 (43%) 1.74 (0.98;3.10) 0.06 40 (17%) 0.58 (0.31;1.07) 0.08
Had MSSA previously No 130 (33%) 179 (46%) 1.00 84 (21%) 1.00
Yes 6 (26%) 13 (57%) 0.62 (0.22;1.77) 0.37 4 (17%) 0.73 (0.23;2.36) 0.60
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436 R.R. Miller et al.intermittent carriers of one or multiple spa-types and non-
carriers are shown in Table 2 and Supplementary Table 4.
Intermittent carriers had median (IQR) carrier index 0.33
(0.16e0.57) for their most commonly observed spa-type.
Consistent carriers of one spa-type long-term appeared to
differ in the CC of the spa-type they carried consistently,
being more likely to carry CC22 (which includes EMRSA-
15) (adjusted P Z 0.03) and somewhat less likely to carry
CC15 (PZ 0.08) than intermittent carriers. Consistent car-
riers of one spa-type long-term were also less likely to have
received anti-staphylococcal antibiotics, had fewer other
household members and longer times since their last outpa-
tient appointment (P Z 0.04, 0.02 and 0.01 respectively).Discussion
In this large primary care-based study, we found 32%
participants positive for S. aureus on a recruitment nasal
swab, remarkably similar to S. aureus prevalence in other
population studies, suggesting our results are likely gener-
alisable.1,2,11 However, unlike the majority of other
studies, our median follow-up of two years with bi-
monthly swabs allowed detailed investigation of long-term
carriage, and spa-typing every isolate enabled discrimina-
tion at the strain rather than the species level.
Our findings are compatible with a carriage spectrum in
which the extremes are characterised by two phenotypes
present at different proportions in recruitment-positives
and negatives. The first is highly transient carriage,
exemplified by most acquisitions in recruitment-
negatives, who carried for a median of only two months.
Interestingly the rate of acquisition of new spa-types was
similar and approximately constant in recruitment-
negatives and positives, and recruitment-positives lost
newly acquired strains at only slightly slower rates than
recruitment-negatives, suggesting that both are susceptible
to highly transient carriage. The second carriage phenotype
is long-term S. aureus carriage, exemplified by the much
slower loss of recruitment spa-types in recruitment-
positives, and low loss rates >4e6 months after acquisition
in both recruitment-positives and negatives.
Our data could not fully support or refute the presence of
a third “truly persistent” carriage phenotype as the pro-
portion classified as consistent long-termcarriers continued
to decline as length of follow-up increased throughout the
study. Further follow-up will be necessary to assess this
definitively. Using our method of analysis, truly persistent
carriage would be indicated by loss rates reducing to zero
some time after 24e30 months (Supplementary Fig. 1(b))
with no further change in the proportion still carrying S.
aureus (Figs. 4(b) and 5(a)). Other studies have defined
“persistence” using more frequent sampling over shorter
timescales,11,12 sometimes using quantitative culture27;
when this study was set-up resource-constraints required
a compromise between less intensive long-term versus
more intensive short-term follow-up. One important study
limitation is clearly the lack of a sampling point earlier
than one month, e.g. at one week, which would have
enabled us to investigate “persistent” carriers definedusing
van Nouwen’s rule.12 The fact that these “persistent” car-
riers have been shown to differ significantly in
Dynamics of S. aureus carriage 437characteristics such as clearance of a S. aureus inoculum,19
and host genetics,13 indicates that at least a subgroup form
a distinct sub-population. However, we did have a sampling
point at one month, and Fig. 5(a) demonstrates a clear
ongoing linear decline in consistent long-term carriage
even in those with two initial positive cultures, suggesting
that a proportion with “persistent” carriage will not carry
S. aureus long-term. In fact five of 17 “persistent” carriers
(29%, 95%CI 10e56%)were not carrying S. aureus eight years
later in the original study of Van den Bergh.11 Since van Nou-
wen et al. found that two qualitative and two
qualitative þ quantitative cultures had almost identical
performance for classifying “persistence” in a validation
set,12 it is unclear that doing quantitative cultures in our
study would have materially altered this finding; we priori-
tised spa-typing all isolates over such quantitative culture.
Our findings suggest that “persistence” as previously
defined12,27 could overestimate long-term carriage at the
species level, and thus that there is no quick and reliable
method to identify consistent long-term S. aureus carriers.
Furthermore, 15% of long-term carriers at the species level
in our study did not carry the same spa-type consistently
(similarly to Ref.28). Whilst colonised with S. aureus long-
term, the arrival of a new strain may still have the potential
to alter outcomes, similarly to acquiring S. aureus de novo,5
highlighting the importance of using strain typing to iden-
tify truly persistent carriage. Assuming those followed
long enough to identify this group were representative,
“spa-consistent” long-term carriers would comprise 17% of
those enrolled. Interestingly, two-thirds of these “spa-
consistent” long-term carriers never had any other strain
identified despite the long follow-up and the fact that
multi-strain colonisation was actively investigated.
We found that the rate of new acquisitions increased
linearly through the study (Fig. 3) and the proportion never
observed to carry correspondingly decreased linearly
(Fig. 5(b)). Our data are thus compatible with van Belkum’s
suggestion, based on experimental inoculation studies,19
that there are no true S. aureus non-carriers, i.e. that a
fourth “never carriage” group does not exist. Whilst 90 par-
ticipants returning 12 swabs never had S. aureus isolated
from any study sample, the highly transient carriage that
was observed suggests it could have been found at interme-
diate timepoints. Extrapolating from Fig. 3, 5e10 years
follow-up would be needed to distinguish a never carriage
phenotype (where the cumulative new acquisition proba-
bility would plateau) from continued acquisitions (where
the cumulative new acquisition probability would reach
100%). The former scenario would imply that host, rather
than bacterial, genetics determines this phenotype.
Despite this being the largest longitudinal study of S.
aureus carriage to date, we failed to find strong predictors
of gain, loss or persistence, possibly reflecting multifactorial
causes and limited power to detect modest absolute differ-
ences of around 10%, given that the study was powered to
detect 15% differences. Overall effects on loss, gain, and
persistencewere broadly compatible, although these reflect
subtly different aspects of the underlying dynamics. Host ef-
fects likely reflected potential for S. aureus exposure
(household members, students), underlying host-immunity
(age, previous MSSA), and complex effects of health status
(long-term illness, recent outpatient appointments).Interestingly receiving anti-staphylococcal antibiotics
significantly increased the likelihood of losing S. aureus in
the next swab, but also increased the likelihood of later
acquisition. This is consistent with antibiotics only tempo-
rarily removing S. aureus from the nares, followed by re-
acquisition from other body sites/close contacts, as in one
study of artificial decolonisation and re-colonisation.19
These findings question the validity of S. aureus eradication
as a concept, and suggest that reducing S. aureus load
around high-risk procedures (e.g. through decontamina-
tion/prophylaxis pre-surgery) is amore biologically plausible
approach to reducing S. aureus infection risk.
Unexpectedly, we found large effects of spa-type on
acquisition and long-term consistent carriage. Compared
to other CCs, more new spa-types were gained if CC8 or
CC15 were present either at recruitment or in the previous
swab, and CC15 in particular was less likely to be carried
consistently long-term than intermittently, similar to find-
ings based on using only two swabs to define “persis-
tence”.29 Whilst pre-existing colonisation did not affect S.
aureus loss at the species level, co-carriage was signifi-
cantly associated with loss of the original strain. This dem-
onstrates the highly dynamic nature of carried populations,
and that nasal competition from particular strains is an
important factor in co-carriage in vivo. Interestingly, CC8
includes USA300, so tolerance of co-carriage might
contribute to the success of this lineage if it is also more
readily acquired (not evaluable here due to low numbers
of acquisitions of specific clones). Only CC22 was found in
significantly more long-term carriers; this CC includes
EMRSA-15, again potentially explaining this clone’s success.
This finding was implied by analyses of loss (Table 1). How-
ever, clearly the fact that the most widely dispersed CC8
and CC22 strains contain mecA is a confounding factor.
Our study had four main limitations. Firstly, participants
were swabbed only in the nares, which likely missed some
carriage even at the timepoints assayed30,31; a recent study
suggests that this may have particularly underestimated
carriage in younger people.32 However, swabbing of the
nares enabled participant self-swabbing, which was vital
for our study and was recently shown to have reasonable
accuracy.33 Secondly, the bi-monthly sampling interval
may have missed some transient carriage. However, it
seems probable that those consistently observed to carry
the same spa-type for >20 months (n Z 137) would have
also carried this spa-type at intermediate timepoints.
Thirdly, smoking status was not available, but has been
associated with reduced carriage in cross-sectional stud-
ies.34e36 Finally, since we combined unrelated CCs with
less than ten isolates into a single group for analysis, and
since numbers of isolates even in some larger CCs were still
relatively modest, our findings on CCs should be confirmed
in future studies. Our choice to perform overnight culture
of swabs in enrichment medium only and not use direct
plating may be seen both as a limitation and a strength. A
limitation is that quantitation, which can predict persistent
carriage,12 becomes impossible. A strength is that enrich-
ment increases the sensitivity of the test and since re-
sources prevented us from identifying isolates using both
methods, we opted to maximise detection.
In conclusion, two years follow-up is insufficient to
identify whether truly persistent long-term or “never”
438 R.R. Miller et al.carriage phenotypes exist; this will require five-ten years
follow-up (continuing in this study). Long-term S. aureus car-
riage at the S. aureus species level is not the same as long-
term carriage at the spa-type level (observed in 57% and
49% of recruitment-positives respectively). Thus to identify
long-term carriage reliably requires swabs over at least
two years and spa-typing, including systematic methods for
identifying co-colonisation, limiting the potential for accu-
rate identification of long-term consistent carriage pheno-
types for future genome-wide association studies.
However, we have conclusively demonstrated bacterial
lineage-specific effect on carriage dynamics. The transient
carriage of spa-types with/without underlying persistent
carriage, the lack ofmodifiable risk factors and the strong in-
fluence of antibiotics and strain-type on carriage acquisi-
tion, loss and persistence, highlights the dynamic nature of
S. aureus as a human commensal. This emphasises the impor-
tance of focussing prevention efforts on reducing universal
infection risk rather than eradication of carriage in
individuals.37,38
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